Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia

European Journal of Internal Medicine

Volumn 10, Issue 1, 1999, Pages 33-39

  Assmann, G ^a   Huwel D ^b   Schussman, K M ^b   Smilde, J G ^c   Kosling M ^d   Withagen, A J A M ^e   Wunderlich, J ^f   Stoel, I ^g   Van Dormaal, J J ^h   Neuss, J ⁱ   Oldenbroek, C ^j   Cuppers M C ^k   Von Eckardstein, A ^a   Schulte, H ^a   Wagner, B ^l   McLain, R ^m   Black, D M ^m  

^a Inst Klin Chem L   (Germany)

^b D 58239 ^*  (Germany)

^c 'Refaja' Boerhavestraat 1 N   (Netherlands)

^d D 28209   (Germany)

^e REINIER DE GRAAF HOSPITAL   (Netherlands)

^f Müllerstr 139   (Germany)

^g Diakonessenhuis 'Refaja'   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Wilhelmstr 26   (Germany)

^j Westfries Gasthuis   (Netherlands)

^k Internist   (Germany)

^l M   (Germany)

^m PFIZER INC   (United States)

more..

Author keywords

Atorvastatin; Coronary disease; Hydroxymethylglutaryl CoA reductase; Hypercholesterolemia; LDL cholesterol

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; RASH;

EID: 0344690047     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(99)00011-4     Document Type: Article

References (33)

1. Levy R.I. Review: declining mortality in coronary heart disease. Arteriosclerosis. 1:1981;312-325.
2. Lipid Research Clinics Program, The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease, J. Am. Med. Assoc. 151 (1984) 351-364.
3. Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, J. Am. Med. Assoc. 151 (1984) 365-374.
4. Brown G., Albers J.J., Fisher L.D.et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323:1990;1289-1298.
5. Stewart B.F., Brown B.G., Zhao X.et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J. Am. Coll. Cardiol. 23:1994;899-906.
6. Prevention of coronary heart disease: scientific background and new clinical guidelines, Recommendations of the European Atherosclerosis Society prepared by the International Task Force for prevention of coronary heart disease, Nutr. Metab. Cardiovasc. Dis. 2 (1992) 113-156.
7. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II), J. Am. Med. Assoc. 269 (1993) 3015-3023.
8. Illingworth E.R. New horizons in combination drug therapy for hypercholesterolemia. Cardiology. 76(suppl):1989;83-100.
9. Nawrocki J.W., Weiss S.R., Davidson M.H.et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15:1995;678-682.
10. Curves Investigators, Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81:1998;582-587.
11. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J.et al. Efficacy and safety of a new HMG-CoA reductase inhibitor in patients with hypertriglyceridemia. J. Am. Med. Assoc. 275:1996;128-133.
12. Black D.M., Bakker-Arkema R.G., Nawrocki J.W. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch. Int. Med. 158:1998;577-584.
13. Bristol-Myers Squibb Pravachol® prescribing information, in: Physicians' Desk Reference, Medical Economics Data, A Division of Medical Economics, Montvale, NJ, 1998, pp. 808-811.
14. Bradford R.H., Shear C.L., Chremos A.N.et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151:1991;43-49.
15. Hunninghake D.B., Knopp R.H., Schonfeld G.et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia: I. A dose-response study. Atherosclerosis. 85:1990;81-89.
16. Jungnickel P.W., Cantral K.A., Maloley P.A. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin. Pharm. 11(8):1992;677-689.
17. Jacobson T.A., Chin M.M., Fromell G.J.et al. Fluvastatin with or without niacin for hypercholesterolemia. Am. J. Cardiol. 74:1994;149-154.
18. Banga J.D., Jacotot B., Pfister P.et al. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. Am. J. Med. 96(Suppl A):1994;87S-93S.
19. Henwood J.M., Heel R.C. Lovastatin - A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs. 36:1988;429-454.
20. Kostner G., Gavish D., Leopold B.et al. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 80:1989;1313-1319.
21. The Pravastatin Multinational Study Group for Cardiac Risk Patients Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am. J. Cardiol. 72:1993;1031-1037.
22. Pitt B., Mancini G.B.J., Ellis S.G.et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26:1995;1133-1139.
23. Crouse J.R., Byington R.P., Bond M.G.et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 75:1995;455-459.
24. Jukema J.W., Bruschke V.G., van Boven A.J.et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 91:1995;2528-2540.
25. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
26. Salonen R., Nyyssönen K., Porkkala E.et al. Kuopio atherosclerosis prevention study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 92:1995;1758-1764.
27. Frick M.H., Elo O., Haapa K.et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 317:1987;1237-1245.
28. Carlson L.A., Bottiger L.E. Ischemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1:1972;865-868.
29. Scandinavian Simvastatin Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
30. The Long-term intervention with pravastatin in ischemic disease (LIPID) study group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357.
31. Sacks P.M., Pfeffer M.A., Moye L.A.et al. For the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
32. Watts G.F., Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr. Opin. Lipidology. 7:1996;341-355.
33. Hunninghake D.B. HMG-CoA reductase inhibitors. Curr. Opin. Lipidology. 3:1992;22-28.